• Mary Larson
• ,  Contributor
• 28 August 2018, 02:08 pm

there are only two companies with approved CAR-T cell therapies at this time, and they do create a small sector with new issues and opportunities all their own.

   0   Reply (0)   Edit    Delete

• John Welch
• ,  Contributor
• 28 August 2018, 02:08 pm

there are other players in this game as well- companies that deal exclusively with the European market but are listed on the NYSE. It would be good to look at the market as a whole rather than driven by the few.

   0   Reply (0)   Edit    Delete

• Scott
• ,  Contributor
• 28 August 2018, 02:08 pm

Very exciting developments.

   0   Reply (0)   Edit    Delete

• Jesse
• ,  Contributor
• 28 August 2018, 02:08 pm

Gilead has a Zacks Rank #1 (Strong Buy).

   0   Reply (0)   Edit    Delete

• John R
• ,  Contributor
• 28 August 2018, 02:08 pm

GILD\'s, KITE should be worth $20 billion by now.

   0   Reply (0)   Edit    Delete

• DoubleD
• ,  Contributor
• 28 August 2018, 02:08 pm

GILD\'s problem, KITE\'s a lead balloon...

   0   Reply (0)   Edit    Delete